Interferon‐free therapy for genotype 1 hepatitis C in liver transplant recipients: Real‐world experience from the hepatitis C therapeutic registry and research network
Robert S. Brown(Cornell University), Norah A. Terrault(University of Southern California), Christine M. Durand(University of Maryland, Baltimore), Thomas G. Stewart(University of North Carolina at Chapel Hill), Adrian M. Di Bisceglie(Saint Louis University), Paul Y. Kwo(Palo Alto University), James R. Burton(University of Colorado Denver), K. Rajender Reddy(Hospital of the University of Pennsylvania), R. Todd Stravitz(Virginia Commonwealth University), Jacqueline G. O’Leary(Veterans Health Administration), David R. Nelson(Harvard University Press), Giuseppe Morelli(University of Florida), Catherine Frenette(Scripps Clinic), Michael Fried(University of North Carolina at Chapel Hill), Alexander Kuo(Cedars-Sinai Medical Center)
Cited by 105
Related Papers
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
|New England Journal of Medicine|2002|3.3k
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
|The Lancet|2014|2.2k
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
|New England Journal of Medicine|2013|1.8k
Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma
|JNCI Journal of the National Cancer Institute|2008|1.7k
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
|New England Journal of Medicine|2014|1.1k